Phage therapy targeting Escherichia coli - a story with no end?

Loading...
Thumbnail Image
Files
1749.pdf(195.92 KB)
Accepted Version
Date
2016-11-09
Authors
Bolocan, Andrei Sorin
Callanan, Julie
Forde, Amanda
Ross, R. Paul
Hill, Colin
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
Published Version
Research Projects
Organizational Units
Journal Issue
Abstract
Bacteriophages (phages) or bacterial viruses have long been proposed as an alternative therapy against antibiotic-resistant bacteria such as Escherichia coli. Even though poorly documented in the scientific literature, a long clinical history of phage therapy in countries such as Russia and Georgia suggests potential value in the use of phages as antibacterial agents. Escherichia coli is responsible for a wide range of diseases, intestinal (diarrhoea) and extraintestinal (UTI, septicaemia, pneumoniae, meningitis), making it an ideal target for phage therapy. This review discusses the latest research focusing on the potential of phage therapy to tackle E. coli-related illnesses. No intact phages are approved in EU or USA for human therapeutic use, but many successful in vitro and in vivo studies have been reported. However, additional research focused on in vivo multispecies models and human trials are required if phage therapy targeting E. coli pathotypes can be a story with happy end.
Description
Keywords
Phage therapy , AIEC , UTI , STEAEC
Citation
Bolocan, A. S., Callanan, J., Forde, A., Ross, R. P. and Hill, C. (2016) 'Phage therapy targeting Escherichia coli - a story with no end?', Fems Microbiology Letters, 363(22), fnw256 (5pp). doi:10.1093/femsle/fnw256
Link to publisher’s version
Copyright
© 2016, FEMS. All rights reserved. This is a pre-copyedited, author-produced version of an article accepted for publication in FEMS Microbiology Letters following peer review. The version of record: Bolocan, A. S., Callanan, J., Forde, A., Ross, P. and Hill, C. (2016) 'Phage therapy targeting Escherichia coli - a story with no end?', Fems Microbiology Letters, 363(22), fnw256 (5pp) is available online at http://dx.doi.org/10.1093/femsle/fnw256